Premenstrual Syndromes : PMS and PMDD - Rutuja :: The site ...

78 THE PREMENSTRUAL SYNDROMES
levels in association with increased anxiety in the female rat.
Brain Res 2001; 910:55–66.
30. Biggio G, Follesa P, Sanna E et al. GABA A -receptor plasticity
during long-term exposure to and withdrawal from progesterone.
Int Rev Neurobiol 2001; 46:207–41.
31. Concas A, Follesa P, Barbaccia ML et al. Physiological modulation
of GABA(A) receptor plasticity by progesterone metabolites.
Eur J Pharmacol 1999; 375:225–35.
32. Follesa P, Floris S, Tuligi G et al. Molecular and functional
adaptation of the GABA(A) receptor complex during pregnancy
and after delivery in the rat brain. Eur J Neurosci 1998;
10:2905–12.
33. Follesa P, Porcu P, Sogliano C et al. Changes in GABA A receptor
gamma 2 subunit gene expression induced by long-term administration
of oral contraceptives in rats. Neuropharmacology
2002; 42:325–36.
34. Smith SS. Withdrawal properties of a neuroactive steroid: implications
for GABA A receptor gene regulation in the brain and
anxiety behavior. Steroids 2002; 67(6):519–28.
35. Concas A, Serra M, Atsoggiu T et al. Foot-shock stress and anxiogenic
beta-carbolines increase t-[35S]butylbicyclo-phosphorothionate
binding in the rat cerebral cortex, an effect opposite to
anxiolytics and gamma-aminobutyric acid mimetics. J Neurochem
1988; 51:1868–76.
36. Sundström Poromaa I, Smith S, Gulinello M. GABA receptors,
progesterone and premenstrual dysphoric disorder. Arch Womens
Ment Health 2003; 6(1):23–41.
37. N-Wihlbäck AC, Sundström-Poromaa I, Bäckström T. Action
by and sensitivity to neuroactive steroids in menstrual cycle
related CNS disorders. Psychopharmacology (Berl) 2006;
186(3):388–401.
38. Bitran D, Klibansky DA, Martin GA. The neurosteroid pregnanolone
prevents the anxiogenic-like effect of inescapable
shock in the rat. Psychopharmacology (Berl) 2000; 151(1):31–7.
39. Molina-Hernandez M, Tellez-Alcantara NP. Antidepressant-like
actions of pregnancy, and progesterone in Wistar rats forced to
swim. Psychoneuroendocrinology 2001; 26:479–91.
40. Steimer T, Driscoll P, Schulz PE. Brain metabolism of progesterone,
coping behaviour and emotional reactivity in male rats
from two psychogenetically selected lines. J Neuroendocrinol
1997; 9:169–75.
41. Uzunova V, Sheline Y, Davis JM et al. Increase in the cerebrospinal
fluid content of neurosteroids in patients with unipolar
major depression who are receiving fluoxetine or fluvoxamine.
Proc Natl Acad Sci USA 1998; 95(6):3239–44.
42. Brambilla P, Perez J, Barale F et al. GABAergic dysfunction in
mood disorders. Mol Psychiatry 2003; 8:721–37.
43. Drugan RC, Morrow AL, Weizman R et al. Stress-induced
behavioral depression in the rat is associated with a decrease in
GABA receptor-mediated chloride ion flux and brain benzodiazepine
receptor occupancy. Brain Res 1989; 487:45–51.
44. Gruen RJ, Wenberg K, Elahi R et al. Alterations in GABA A
receptor binding in the prefrontal cortex following exposure to
chronic stress. Brain Res 1995; 684:112–14.
45. Serra M, Pisu MG, Littera M et al. Social isolation-induced
decreases in both the abundance of neuroactive steroids and
GABA(A) receptor function in rat brain. J Neurochem 2000;
75:732–40.
46. Majewska MD, Harrison R, Schwartz R. Steroid hormone
metabolites are barbiturate-like modulators of the GABA receptor.
Science 1986; 232:1004.
47. Sanacora G, Mason GF, Krystal JH. Impairment of GABAergic
transmission in depression: new insights from neuroimaging
studies. Crit Rev Neurobiol 2000; 14:23–45.
48. Malizia AL, Cunningham VJ, Bell CJ et al. Decreased
brain GABA(A)-benzodiazepine receptor binding in panic
disorder: preliminary results from a quantitative PET study.
Arch Gen Psychiatry 1998; 55:715–20.
49. Rapkin A, Morgan M, Goldman L et al. Progesterone metabolite
allopregnanolone in women with premenstrual syndrome.
Obstet Gynecol 1997; 90(5):709–14.
50. Monteleone P, Luisi S, Tonetti A et al. Allopregnanolone concentrations
and premenstrual syndrome. Eur J Endocrinol 2000;
142:269–73.
51. Schmidt PJ, Purdy RH, Moore PH Jr et al. Circulating levels of
anxiolytic steroids in the luteal phase in women with premenstrual
syndrome and in control subjects. J Clin Endocrinol
Metab 1994: 79(5):1256–60.
52. Wang M, Seippel L, Purdy RH et al. Relationship between
symptom severity and steroid variation in women with premenstrual
syndrome: study on serum pregnenolone, pregnenolone
sulfate, 5 alpha-pregnane-3,20-dione and 3 alpha-hydroxy-5
alpha-pregnan-20-one. J Clin Endocrinol Metab 1996;
81(3):1076–82.
53. Girdler SS, Straneva PA, Light KC et al. Allopregnanolone levels
and reactivity to mental stress in premenstrual dysphoric disorder.
Biol Psychiatry 2001; 49(9):788–97.
54. Sundström I, Andersson A, Nyberg S et al. Patients with premenstrual
syndrome have a different sensitivity to a neuroactive
steroid during the menstrual cycle compared to control subjects.
Neuroendocrinology 1998; 67(2):126–38.
55. Sundström I, Nyberg S, Bäckstrom T. Patients with premenstrual
syndrome have reduced sensitivity to midazolam compared
to control subjects. Neuropsychopharmacology 1997;
17(6):370–81.
56. Friedman L, Gibbs TT, Farb DH. Gamma-aminobutyric acid
A receptor regulation: chronic treatment with pregnanolone
uncouples allosteric interactions between steroid and benzodiazepine
recognition sites. Mol Pharmacol 1993; 44:191–7.
57. Yu R, Follesa P, Ticku MK. Down-regulation of the GABA
receptor subunits mRNA levels in mammalian cultured cortical
neurons following chronic neurosteroid treatment. Brain Res
Mol Brain Res 1996; 41:163–8.
58. Carl P, Hogskilde S, Nielsen JW et al. Pregnanolone emulsion.
A preliminary pharmacokinetic and pharmacodynamic study
of a new intravenous anaesthetic agent. Anaesthesia 1990;
45:189–97.
59. Bitran D, Hilvers RJ, Kellogg CK. Anxiolytic effects of 3
alpha-hydroxy-5 alpha[beta]-pregnan-20-one: endogenous
metabolites of progesterone that are active at the GABAA receptor.
Brain Res 1991; 561:157–61.
60. Landgren S, Aasly J, Backstrom T et al. The effect of progesterone
and its metabolites on the interictal epileptiform discharge
in the cat’s cerebral cortex. Acta Physiol Scand 1987; 131:33–42.
61. Andreen L, Sundstrom-Poromaa I, Bixo M et al. Relationship
between allopregnanolone and negative mood in postmenopausal
women taking sequential hormone replacement
therapy with vaginal progesterone. Psychoneuroendocrinology
2005; 30:212–24.
62. Miczek KA, Fish EW, DeBold JF. Neurosteroids, GABA A receptors,
and escalated aggressive behavior. Horm Behav 2003;
44(3):242–57.
63. Roy-Byrne PP, Rubinow DR, Gwirtsman H et al. Cortisol
response to dexamethasone in women with premenstrual syndrome.
Neuropsychobiology 1986; 16(2–3):61–3.
64. Roca CA, Schmidt PJ, Altemus M et al. Differential menstrual
cycle regulation of hypothalamic–pituitary–adrenal axis in women
with premenstrual syndrome and controls. J Clin Endocrinol
Metab 2003; 88(7):3057–63.
65. Rapkin AJ, Buckman TD, Sutphin MS et al. Platelet monoamine
oxidase B activity in women with premenstrual syndrome. Am J
Obstet Gynecol 1988; 159:1536–40.